Tesamorelin Research for Growth Hormone Optimization
An evidence-based overview of research examining Tesamorelin in the context of growth hormone optimization. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tesamorelin restores physiologic GH pulsatility rather than providing continuous GH levels, distinguishing it from exogenous GH replacement. This preserves natural feedback systems and may offer safety advantages including maintained overnight GH patterns and preserved somatostatin regulation.
Clinical trials consistently show mean IGF-1 increases of approximately 81% from baseline, normalizing levels in GH-insufficient populations. The pulsatile release pattern mimics natural physiology better than direct GH injection.
The GHRH receptor agonist mechanism ensures that GH release remains under physiologic control, potentially reducing risks of IGF-1 excess and GH-related side effects compared to supraphysiologic GH dosing.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Growth Hormone Optimization
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Tesamorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.